secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001104659-25-045309
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Positive topline results from VIRAGE Phase 2b trial: VCN-01+SoC improves OS, PFS, DoR in metastatic pancreatic cancer
--------------------------------------------------------------------------------

- Median OS 10.8 vs 8.6 months for VCN-01+SoC vs SoC alone (HR=0.57, p=0.0546).
- Median PFS 7.0 vs 4.6 months (HR=0.55, p=0.0105).
- Median DoR doubled to 11.2 vs 5.4 months (HR=0.22, p=0.0035).
- 2-dose VCN-01 + ≥4 cycles SoC subgroup: median OS 14.8 vs 11.6 months (HR=0.44, p=0.046).
- Safety met primary endpoint; AEs transient/reversible, consistent with prior trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465925045309/0001104659-25-045309-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465925045309/tm2514050d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-045309

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer